MASSAI, LARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.455
EU - Europa 4.088
AS - Asia 3.178
SA - Sud America 341
Continente sconosciuto - Info sul continente non disponibili 179
AF - Africa 80
OC - Oceania 35
Totale 14.356
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.316
RU - Federazione Russa 1.151
IT - Italia 982
CN - Cina 897
PL - Polonia 869
SG - Singapore 851
HK - Hong Kong 470
VN - Vietnam 309
BR - Brasile 269
KR - Corea 254
IE - Irlanda 206
SE - Svezia 145
DE - Germania 140
NL - Olanda 140
FR - Francia 119
FI - Finlandia 116
GB - Regno Unito 111
CA - Canada 86
IN - India 77
BD - Bangladesh 75
JP - Giappone 48
ID - Indonesia 37
AU - Australia 34
JO - Giordania 34
MX - Messico 27
AR - Argentina 26
ES - Italia 25
NG - Nigeria 18
ZA - Sudafrica 18
UA - Ucraina 17
BE - Belgio 16
IQ - Iraq 16
TR - Turchia 15
CH - Svizzera 14
CI - Costa d'Avorio 13
EC - Ecuador 13
IL - Israele 13
VE - Venezuela 12
PK - Pakistan 9
AT - Austria 8
SA - Arabia Saudita 8
TW - Taiwan 8
MA - Marocco 7
RO - Romania 7
AE - Emirati Arabi Uniti 6
BH - Bahrain 6
CL - Cile 6
CO - Colombia 6
CZ - Repubblica Ceca 6
PH - Filippine 6
IR - Iran 5
JM - Giamaica 5
UZ - Uzbekistan 5
AL - Albania 4
KE - Kenya 4
AZ - Azerbaigian 3
BG - Bulgaria 3
BJ - Benin 3
DO - Repubblica Dominicana 3
DZ - Algeria 3
EG - Egitto 3
KG - Kirghizistan 3
KZ - Kazakistan 3
MY - Malesia 3
NI - Nicaragua 3
PE - Perù 3
PY - Paraguay 3
BB - Barbados 2
GD - Grenada 2
HN - Honduras 2
KH - Cambogia 2
NP - Nepal 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
UY - Uruguay 2
AM - Armenia 1
AO - Angola 1
AW - Aruba 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CY - Cipro 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HT - Haiti 1
KW - Kuwait 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
ML - Mali 1
Totale 14.166
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.268
Warsaw 864
Ashburn 799
Singapore 594
Fairfield 430
Hong Kong 418
Seoul 250
San Jose 247
Woodbridge 230
Hefei 220
Chandler 219
Florence 207
Dublin 205
Beijing 179
Houston 179
Seattle 170
Milan 162
Cambridge 159
Council Bluffs 139
Wilmington 133
Ann Arbor 120
Buffalo 103
Los Angeles 102
Ho Chi Minh City 91
New York 84
Amsterdam 81
Lauterbourg 80
Lawrence 77
Rome 76
Altamura 71
Dallas 64
Princeton 64
Hanoi 61
Munich 50
Helsinki 46
The Dalles 44
Moscow 43
Groningen 42
Tokyo 41
Boston 38
Shanghai 33
Kent 32
Bologna 30
Turku 30
Melbourne 29
Mumbai 29
Medford 28
São Paulo 28
Jakarta 27
Clifton 25
Naples 25
Toronto 25
Orem 24
San Diego 24
Chicago 22
Da Nang 22
London 22
Boardman 21
Turin 19
Abuja 18
Jacksonville 17
Montreal 17
Frankfurt am Main 16
Paris 16
Brussels 15
Mexico City 15
Barcelona 14
Phoenix 14
Abidjan 13
Brooklyn 13
Palermo 13
Redondo Beach 13
Denver 12
Evanston 12
Haiphong 12
Bristol 11
Guangzhou 11
Atlanta 10
Bengaluru 10
Figino 10
Tianjin 10
West Jordan 10
Baghdad 9
Belo Horizonte 9
Campinas 9
Lappeenranta 9
Stockholm 9
Chennai 8
Dong Ket 8
Falkenstein 8
Johannesburg 8
Manchester 8
Norwalk 8
Pistoia 8
Poplar 8
Rio de Janeiro 8
The Bronx 8
Verona 8
Wuhan 8
Charlotte 7
Totale 9.395
Salva come PNG Salva come JPEG
Nome #
The leading established metal-based drugs: a revisitation of their relevant physico-chemical data 667
Gold Compounds as Anticancer Agents: A Systematic Study of Gold–Protein Metalation 347
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 342
Bioconjugations of proteins with 19F and nitroxide tags for in vitro and in cell characterization 341
A first-in-class and a fished out anticancer platinum compound:: Cis -[PtCl2(NH3)2] and cis -[PtI2(NH3)2] compared for their reactivity towards DNA model systems 336
Reactions of model proteins with aurothiomalate, a clinically established gold(I) drug: The comparison with auranofin 322
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 322
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 308
Evidence that the antiproliferative effects of auranofin in Saccharomyces cerevisiae arise from inhibition of mitochondrial respiration 289
Design, synthesis and characterisation of new chimeric ruthenium(ii)-gold(i) complexes as improved cytotoxic agents 270
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 255
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 254
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 244
Determinants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD Investigation 242
Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles 222
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. 220
Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes 207
[Au(9-methylcaffein-8-ylidene)2]+/DNA Tel23 System: Solution, Computational, and Biological Studies 206
Elucidating the reactivity of Pt(II) complexes with (O,S) bidentate ligands towards DNA model systems 197
Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin 195
Au2phen and Auoxo6, Two Dinuclear Oxo-Bridged Gold({III}) Compounds, Induce Apoptotic Signaling in Human Ovarian A2780 Cancer Cells 191
Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents 191
Bioconjugation of the gold drug auranofin to human ferritin yields a potent cytotoxin 185
Pyrene-Containing Polyamines as Fluorescent Receptors for Recognition of PFOA in Aqueous Media 179
The mode of action of anticancer gold-based drugs: a structural perspective 179
Interactions of the organogold(III) compound Aubipyc with the copper chaperone Atox1: A joint mass spectrometry and circular dichroism investigation 178
Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems 176
Protonation of cyclen-based chelating agents containing fluorescent moieties 175
Large Protein Assemblies for High-Relaxivity Contrast Agents: The Case of Gadolinium-Labeled Asparaginase 173
Gold-Based Metal Drugs as Inhibitors of Coronavirus Proteins: The Inhibition of SARS-CoV-2 Main Protease by Auranofin and Its Analogs 172
Cisplatin binding to human serum albumin: a structural study 171
Anticancer Ruthenium(III) Complex KP1019 Interferes with ATP-Dependent Ca(2+) Translocation by Sarco-Endoplasmic Reticulum Ca(2+) -ATPase (SERCA) 170
Organogold(III) compounds as experimental anticancer agents: chemical and biological profiles 170
Chemical Modification of Auranofin Yields a New Family of Anticancer Drug Candidates: The Gold(I) Phosphite Analogues 168
Interactions of Gold-based drugs with proteins: crystal structure of the adduct formed between Ribonuclease A and a cytotoxic gold(III) compound 166
Comparative NMR metabolomics of the responses of A2780 human ovarian cancer cells to clinically established Pt-based drugs 165
Cyclodextrin Inclusion Complexes of Auranofin and Its Iodido Analog: A Chemical and Biological Study 161
Size dependent biological profiles of PEGylated gold nanorods 160
The effects of two cytotoxic gold(i) carbene compounds on the metabolism of A2780 ovarian cancer cells: mechanistic inferences through NMR analysis 156
The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study 155
Interactions of selected gold(III) complexes with DNA G quadruplexes 155
Reactions of Cytotoxic Metallodrugs with Lysozyme in pure DMSO explored through UV-Vis Absorption Spectroscopy and ESI MS 154
The cisplatin/serum albumin system: A reappraisal 152
19F: A small probe for a giant protein 151
Protein Metalation by Medicinal Gold Compounds: Identification of the Main Features of the Metalation Process through ESI MS Experiments 150
Cell and Cell-Free Mechanistic Studies on Two Gold(III) Complexes with Proven Antitumor Properties 148
Protein metalation by metal-based drugs: reactions of cytotoxic gold compounds with cytochrome c and lysozyme 145
Inhibition of Na+/K+-ATPase and cytotoxicity of a few selected gold(III) complexes 140
Gold compounds: new anticancer drugs candidates. Studies of protein metalation processes 139
Direct detection of iron clusters in L ferritins through ESI-MS experiments 134
Platinum(II) Complexes with O,S Bidentate Ligands: Biophysical Characterization, Antiproliferative Activity, and Crystallographic Evidence of Protein Binding 133
Selected Cytotoxic Gold Compounds cause Significant Inhibition of 20S Proteasome Catalytic Activities 131
Reactions of Medicinal Gold(III) Compounds With Proteins and Peptides Explored by Electrospray Ionization Mass Spectrometry and Complementary Biophysical Methods 128
NMR reveals the metabolic changes induced by auranofin in A2780 cancer cells: Evidence for glutathione dysregulation 128
Mechanistic studies on cytotoxic gold compounds 126
Structure-activity relationships in a series of auranofin analogues showing remarkable antiproliferative properties 125
Mercury binding to proteins disclosed by ESI MS experiments: The case of three organomercurials 124
Gold compounds as cysteine protease inhibitors: perspectives for pharmaceutical application as antiparasitic agents 123
Structural evidences for a secondary gold binding site in the hydrophobic box of lysozyme 122
Studies of cytotoxic gold compounds: interactions with model proteins and with the copper chaperone Atox-1 121
Dirhodium tetraacetate binding to a B-DNA double helical dodecamer probed by X-ray crystallography and mass spectrometry 119
Na/K-ATPase as a target for anticancer metal based drugs: insights into molecular interactions with selected gold(iii) complexes 119
Proteomics as a tool to disclose the cellular and molecular mechanisms of selected anticancer gold compounds 119
Antiproliferative Properties of a Few Auranofin-Related Gold(I) and Silver(I) Complexes in Leukemia Cells and their Interferences with the Ubiquitin Proteasome System 118
Strategies for the design of analogs of auranofin endowed with anticancer potential 117
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: biological and pharmacological implications 116
Unlocking the Power of Human Ferritin: Enhanced Drug Delivery of Aurothiomalate in A2780 Ovarian Cancer Cells 110
On the mechanism of action of arsenoplatins: arsenoplatin-1 binding to a B-DNA dodecamer 106
Cytotoxic Pt(ii) complexes containing alizarin: a selective carrier for DNA metalation 104
Deciphering the role of neutral diruthenium complexes in protein binding 103
Novel NMR-Based Approach to Reveal the ‘Metabolic Fingerprint’ of Cytotoxic Gold Drugs in Cancer Cells 102
Auranofin and its analogs as prospective agents for the treatment of colorectal cancer 90
Reactions of proteins with a few organopalladium compounds of medicinal interest 85
Reactions of Medicinal Gold Compounds with Cathepsin B Explored through Electrospray Mass Spectrometry Measurements 81
Synthesis, chemical characterization, and biological evaluation of a novel auranofin derivative as an anticancer agent 79
Picoplatin binding to proteins: X-ray structures and mass spectrometry data on the adducts with lysozyme and ribonuclease A 77
Enlarging the scenario of site directed 19F labeling for NMR spectroscopy of biomolecules 76
null 68
Cytotoxicity and Binding to DNA, Lysozyme, Ribonuclease A, and Human Serum Albumin of the Diiodido Analog of Picoplatin 55
Editorial: The Golden Future in Medicinal Chemistry: Perspectives and Resources From Old and New Gold-Based Drug Candidates 49
Oxaliplatin bioconjugates with human ferritin obtained by protein surface decoration: Characterization and biological evaluation 45
Antiproliferative properties of a few auranofin-related Gold(I) and Silver(I) complexes in leukemia cells and their interferences with the ubiquitin proteasome system 38
Lipoic acid as a linker to auranofin analogue on nanocellulose 36
Playing with Structural Parameters in the Design of Ruthenium(II)-p-Cymene Complexes as Potential Antibacterial Agents 31
null 31
Reactions with proteins of three novel anticancer platinum(II) complexes bearing N-heterocyclic ligands 28
Modeling the metabolic response of A2780 ovarian cancer cells to gold-based cytotoxic drugs 28
New platinum(II) and palladium(II) complexes with substituted terpyridine ligands: synthesis and characterization, cytotoxicity and reactivity towards biomolecules 27
The impact of albumin conjugation on the cytotoxic properties of cisplatin, oxaliplatin and auranofin in cancer cells 26
Medicinal gold compounds form tight adducts with the copper chaperone Atox-1: Biological and pharmacological implications 24
Protein metalation by metal-based drugs: Reactions of cytotoxic gold compounds with cytochrome c and lysozyme 23
Comparative reactivity of medicinal gold(i) compounds with the cyclic peptide vasopressin and its diselenide analogue 21
Medicinal Au(i) compounds targeting urease as prospective antimicrobial agents: unveiling the structural basis for enzyme inhibition 21
null 21
Protein metalation by two structurally related gold(I) carbene complexes: An ESI MS study 21
null 18
Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study (2022) Inorganic Chemistry 17
Ligand-driven redox behavior of gold(III) complexes: electrochemical insights into stability and biological potential 14
The electrochemical profiles of Auranofin and Aubipyc, two representative medicinal gold compounds: A comparative study 14
Lipoic acid as a linker to Auranofin analogue on nanocellulose 13
Totale 14.346
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.015
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.015
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022420 0 37 28 16 17 23 13 35 25 24 88 114
2022/2023983 97 219 65 70 57 166 127 43 91 10 23 15
2023/2024574 19 38 74 23 34 62 33 119 15 35 75 47
2024/20253.682 133 326 211 454 1.048 517 92 289 175 82 149 206
2025/20265.623 514 643 491 406 524 172 558 330 414 334 697 540
2026/2027334 231 103 0 0 0 0 0 0 0 0 0 0
Totale 14.356